CD52 and lymphopenia: Regarding the usefulness of the algorithm, the action mechanism of alemtuzumab may be responsible for the very low sensitivity observed after induction therapy regarding peripheral lymphocytosis, due to lymphopenia caused by the anti‐CD52 antibody.